Cargando…

Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma

Glioblastoma (GBM) is the most malignant and aggressive form of glioma and is associated with a poor survival rate. Latest generation Tumour Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL)-based therapeutics potently induce apoptosis in cancer cells, including GBM cells, by binding to deat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishna Moorthy, Nivetha, Seifert, Oliver, Eisler, Stephan, Weirich, Sara, Kontermann, Roland E., Rehm, Markus, Fullstone, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706683/ https://www.ncbi.nlm.nih.gov/pubmed/34946664 http://dx.doi.org/10.3390/molecules26247582

Ejemplares similares

Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
por: Boccellato, Chiara, et al.
Publicado: (2021)

Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism
por: Lincoln, Frank A., et al.
Publicado: (2018)

Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids
por: Stöhr, Daniela, et al.
Publicado: (2020)

TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis
por: López-Gómez, Carlos, et al.
Publicado: (2011)

Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism
por: Vetma, Vesna, et al.
Publicado: (2020)

IgG-single-chain TRAIL fusion proteins for tumour therapy
por: Siegemund, Martin, et al.
Publicado: (2018)

Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
por: Hutt, Meike, et al.
Publicado: (2018)

TRAIL Induces Nuclear Translocation and Chromatin Localization of TRAIL Death Receptors
por: Mert, Ufuk, et al.
Publicado: (2019)

Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
por: Wajant, Harald
Publicado: (2019)

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
por: Dufour, Florent, et al.
Publicado: (2016)

Therapeutic targeting of TRAIL death receptors
por: Di Cristofano, Francesca, et al.
Publicado: (2023)

TRAIL and its receptors in cardiac diseases
por: Grisanti, Laurel A.
Publicado: (2023)

Overcoming TRAIL Resistance for Glioblastoma Treatment
por: Deng, Longfei, et al.
Publicado: (2021)

Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
por: Degli-Esposti, Mariapia A., et al.
Publicado: (1997)

Targeting Death Receptor TRAIL-R2 by Chalcones for TRAIL-Induced Apoptosis in Cancer Cells
por: Szliszka, Ewelina, et al.
Publicado: (2012)

TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors
por: Yang, Xi, et al.
Publicado: (2017)

TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill
por: Mohr, Andrea, et al.
Publicado: (2015)

Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells
por: Trivedi, Rachana, et al.
Publicado: (2015)

Tristetraprolin Posttranscriptionally Downregulates TRAIL Death Receptors
por: Lee, Won Hyeok, et al.
Publicado: (2020)

Current approaches in enhancing TRAIL therapies in glioblastoma
por: Thang, Morrent, et al.
Publicado: (2023)

Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
por: Engesæter, Birgit, et al.
Publicado: (2012)

The Combination of TRAIL Treatment and Cancer Cell Selective Expression of TRAIL-Death Receptor DR4 Induces Cell Death in TRAIL-Resistant Cancer Cells
por: Choi, Eunah, et al.
Publicado: (2006)

Enacting Phenomenological Gestalts in Ultra-Trail Running: An Inductive Analysis of Trail Runners’ Courses of Experience
por: Rochat, Nadège, et al.
Publicado: (2018)

Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells
por: Sanlioglu, Ahter D, et al.
Publicado: (2005)

Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients
por: López-Gómez, Carlos, et al.
Publicado: (2013)

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
por: Fleten, Karianne G, et al.
Publicado: (2016)

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
por: Legler, Karen, et al.
Publicado: (2018)

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis
por: Abdulghani, Junaid, et al.
Publicado: (2013)

TRAIL Receptor Signaling Regulation of Chemosensitivity In Vivo but Not In Vitro
por: Menke, Christina, et al.
Publicado: (2011)

Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System
por: Sarhan, Dhifaf, et al.
Publicado: (2014)

Stem cells are resistant to TRAIL receptor-mediated apoptosis
por: Szegezdi, Eva, et al.
Publicado: (2009)

Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling
por: Oh, You-Take, et al.
Publicado: (2021)

Specific anti‐glioma targeted‐delivery strategy of engineered small extracellular vesicles dual‐functionalised by Angiopep‐2 and TAT peptides
por: Zhu, Zhanchi, et al.
Publicado: (2022)

TRAIL combinations: The new ‘trail’ for cancer therapy (Review)
por: REFAAT, ALAA, et al.
Publicado: (2014)

Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy
por: de Looff, Margot, et al.
Publicado: (2019)

Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia
por: Watanabe, Atsushi, et al.
Publicado: (2021)

N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death
por: Dufour, Florent, et al.
Publicado: (2017)

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
por: Belyanskaya, Larisa L, et al.
Publicado: (2007)

TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic
por: Ralff, Marie D., et al.
Publicado: (2020)

Crossed TRAILs
por: Wells, William A.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_smeild43ajbsgjss855nvij10v